Mutz Christopher 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
ANIP: Head of Rare Disease Christopher Mutz Sells Shares
What Happened
- Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals (ANIP), sold a total of 9,037 shares in early March 2026 for aggregate proceeds of approximately $669,986. Transactions: 2,121 shares sold on 2026-03-06 at a weighted avg. $74.22 ($157,421); 3,314 shares surrendered/withheld on 2026-03-07 at $74.04 ($245,369) to cover tax obligations related to restricted stock vesting; and 3,602 shares sold on 2026-03-09 at a weighted avg. $74.18 ($267,196). These were disposals (sales/withholding), not purchases.
Key Details
- Dates & amounts:
- 2026-03-06: Open-market sale, 2,121 sh @ $74.22 = $157,421 (weighted avg; multiple trades at $73.14–$75.00 per footnote).
- 2026-03-07: Shares withheld/surrendered for taxes (F), 3,314 sh @ $74.04 = $245,369 (related to vesting of 6,476 RS; exempt under Rule 16(b)-3).
- 2026-03-09: Open-market sale, 3,602 sh @ $74.18 = $267,196 (weighted avg; multiple trades at $73.27–$74.81).
- Total shares sold/withheld: 9,037; total proceeds ≈ $669,986.
- Footnotes: Sales were executed under a Rule 10b5‑1 plan adopted June 16, 2025 (F1); reported prices are weighted averages across multiple trades (F2, F4); one entry reflects tax-withholding on vested restricted stock (F3).
- Ownership after transaction: not specified in the supplied filing details.
- Timeliness: Filed 2026-03-10 for transactions between 2026-03-06 and 2026-03-09 — the Form 4 appears timely (filed within the SEC’s two business-day window).
Context
- These transactions are sales and tax-withholdings rather than open-market purchases. Sales executed under a 10b5‑1 plan are typically pre-planned and can be routine; tax-withholding reflects vesting of restricted stock rather than a discretionary market sale. No late filing was indicated in the provided information.
Insider Transaction Report
Form 4
Mutz Christopher
HEAD OF RARE DISEASE
Transactions
- Sale
Common Stock
[F1][F2]2026-03-06$74.22/sh−2,121$157,421→ 101,387 total - Tax Payment
Common Stock
[F3]2026-03-07$74.04/sh−3,314$245,369→ 98,073 total - Sale
Common Stock
[F1][F4]2026-03-09$74.18/sh−3,602$267,196→ 94,471 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
- [F2]The shares were sold in multiple trades at prices ranging from $73.14 to $75.00. The price reported above reflects the weighted average sales price.
- [F3]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,476 shares of restricted stock, the grant of which was previously reported.
- [F4]The shares were sold in multiple trades at prices ranging from $73.27 to $74.81. The price reported above reflects the weighted average sales price.
Signature
/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook|2026-03-10